Ultragenyx Pharmaceutical Inc.
RARE
$26.84
$0.542.05%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 13.48% | 20.13% | 20.53% | 26.66% | 33.35% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 13.48% | 20.13% | 20.53% | 26.66% | 33.35% |
| Cost of Revenue | 11.23% | 8.20% | 9.22% | 5.32% | 5.80% |
| Gross Profit | -3.10% | 22.86% | 17.68% | 37.78% | 39.51% |
| SG&A Expenses | 5.26% | 8.47% | 8.29% | 8.17% | 5.95% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 8.78% | 10.20% | 10.93% | 8.22% | 7.90% |
| Operating Income | -3.39% | 0.18% | -1.56% | 7.96% | 11.51% |
| Income Before Tax | -10.69% | -0.75% | -2.72% | 9.68% | 11.13% |
| Income Tax Expenses | 44.99% | 84.50% | 253.60% | 251.47% | 236.46% |
| Earnings from Continuing Operations | -10.85% | -1.04% | -3.68% | 8.96% | 10.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.85% | -1.04% | -3.68% | 8.96% | 10.44% |
| EBIT | -3.39% | 0.18% | -1.56% | 7.96% | 11.51% |
| EBITDA | -4.09% | -0.01% | -1.45% | 9.01% | 13.31% |
| EPS Basic | -3.80% | 7.97% | 8.14% | 24.21% | 26.76% |
| Normalized Basic EPS | 0.68% | 8.23% | 9.40% | 24.79% | 28.29% |
| EPS Diluted | -3.80% | 7.97% | 8.14% | 24.21% | 26.76% |
| Normalized Diluted EPS | 0.68% | 8.23% | 9.40% | 24.79% | 28.29% |
| Average Basic Shares Outstanding | 6.60% | 8.95% | 12.30% | 19.24% | 21.46% |
| Average Diluted Shares Outstanding | 6.60% | 8.95% | 12.30% | 19.24% | 21.46% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |